XFG could become the next dominant COVID variant. Here's what to know about 'Stratus'
This new subvariant is known as XFG (nicknamed "Stratus") and the World Health Organization (WHO) designated it a "variant under monitoring" in late June. XFG is a subvariant of Omicron, of which there are now more than 1,000.
A "variant under monitoring" signifies a variant or subvariant which needs prioritised attention and monitoring due to characteristics that may pose an additional threat compared to other circulating variants.
XFG was one of seven variants under monitoring as of June 25. The most recent addition before XFG was NB.1.8.1 (nicknamed "Nimbus"), which the WHO declared a variant under monitoring on May 23.
Both nimbus and stratus are types of clouds.
Nimbus is currently the dominant subvariant worldwide - but Stratus is edging closer. So what do you need to know about Stratus, or XFG?
XFG is a recombinant of LF.7 and LP.8.1.2 which means these two subvariants have shared genetic material to come up with the new subvariant. Recombinants are designated with an X at the start of their name.
While recombination and other spontaneous changes happen often with SARS-CoV-2, it becomes a problem when it creates a subvariant that is changed in such a way that its properties cause more problems for us.
Most commonly this means the virus looks different enough that protection from past infection (and vaccination) doesn't work so well, called immune evasion. This basically means the population becomes more susceptible and can lead to an increase in cases, and even a whole new wave of COVID infections across the world.
XFG has four key mutations in the spike protein, a protein on the surface of SARS-CoV-2 which allows it to attach to our cells. Some are believed to enhance evasion by certain antibodies.
Early laboratory studies have suggested a nearly two-fold reduction in how well antibodies block the virus compared to LP.8.1.1.
The earliest XFG sample was collected on January 27.
As of June 22, there were 1,648 XFG sequences submitted to GISAID from 38 countries (GISAID is the global database used to track the prevalence of different variants around the world). This represents 22.7% of the globally available sequences at the time.
This was a significant rise from 7.4% four weeks prior and only just below the proportion of NB.1.8.1 at 24.9%. Given the now declining proportion of viral sequences of NB.1.8.1 overall, and the rapid rise of XFG, it would seem reasonable to expect XFG to become dominant very soon.
According to Australian data expert Mike Honey, the countries showing the highest rates of detection of XFG as of mid-June include India at more than 50%, followed by Spain at 42%, and the United Kingdom and United States, where the subvariant makes up more than 30% of cases.
In Australia as of June 29, NB.1.8.1 was the dominant subvariant, accounting for 48.6% of sequences. In the most recent report from Australia's national genomic surveillance platform, there were 24 XFG sequences with 12 collected in the last 28 days meaning it currently comprises approximately 5% of sequences.
When we talk about a new subvariant, people often ask questions including if it's more severe or causes new or different symptoms compared to previous variants. But we're still learning about XFG and we can't answer these questions with certainty yet.
Some sources have reported XFG may be more likely to course "hoarseness" or a scratchy or raspy voice. But we need more information to know if this association is truly significant.
Notably, there's no evidence to suggest XFG causes more severe illness compared to other variants in circulation or that it is necessarily any more transmissible.
Relatively frequent changes to the virus means we have continued to update the COVID vaccines. The most recent update, which targets the JN.1 subvariant, became available in Australia from late 2024. XFG is a descendant of the JN.1 subvariant.
Fortunately, based on the evidence available so far, currently approved COVID vaccines are expected to remain effective against XFG, particularly against symptomatic and severe disease.
Because of SARS-CoV-2's continued evolution, the effect of this on our immune response, as well as the fact protection from COVID vaccines declines over time, COVID vaccines are offered regularly, and recommended for those at the highest risk.
One of the major challenges we face at present in Australia is low COVID vaccine uptake. While rates have increased somewhat recently, they remain relatively low, with only 32.3% of people aged 75 years and over having received a vaccine in the past six months. Vaccination rates in younger age groups are significantly lower.
Although the situation with XFG must continue to be monitored, at present the WHO has assessed the global risk posed by this subvariant as low. The advice for combating COVID remains unchanged, including vaccination as recommended and the early administration of antivirals for those who are eligible.
Measures to reduce the risk of transmission, particularly wearing masks in crowded indoor settings and focusing on air quality and ventilation, are worth remembering to protect against COVID and other viral infections.
Given the number of times this has happened already, it should come as little surprise that we're now faced with yet another new subvariant of SARS-CoV-2, the virus responsible for COVID.
This new subvariant is known as XFG (nicknamed "Stratus") and the World Health Organization (WHO) designated it a "variant under monitoring" in late June. XFG is a subvariant of Omicron, of which there are now more than 1,000.
A "variant under monitoring" signifies a variant or subvariant which needs prioritised attention and monitoring due to characteristics that may pose an additional threat compared to other circulating variants.
XFG was one of seven variants under monitoring as of June 25. The most recent addition before XFG was NB.1.8.1 (nicknamed "Nimbus"), which the WHO declared a variant under monitoring on May 23.
Both nimbus and stratus are types of clouds.
Nimbus is currently the dominant subvariant worldwide - but Stratus is edging closer. So what do you need to know about Stratus, or XFG?
XFG is a recombinant of LF.7 and LP.8.1.2 which means these two subvariants have shared genetic material to come up with the new subvariant. Recombinants are designated with an X at the start of their name.
While recombination and other spontaneous changes happen often with SARS-CoV-2, it becomes a problem when it creates a subvariant that is changed in such a way that its properties cause more problems for us.
Most commonly this means the virus looks different enough that protection from past infection (and vaccination) doesn't work so well, called immune evasion. This basically means the population becomes more susceptible and can lead to an increase in cases, and even a whole new wave of COVID infections across the world.
XFG has four key mutations in the spike protein, a protein on the surface of SARS-CoV-2 which allows it to attach to our cells. Some are believed to enhance evasion by certain antibodies.
Early laboratory studies have suggested a nearly two-fold reduction in how well antibodies block the virus compared to LP.8.1.1.
The earliest XFG sample was collected on January 27.
As of June 22, there were 1,648 XFG sequences submitted to GISAID from 38 countries (GISAID is the global database used to track the prevalence of different variants around the world). This represents 22.7% of the globally available sequences at the time.
This was a significant rise from 7.4% four weeks prior and only just below the proportion of NB.1.8.1 at 24.9%. Given the now declining proportion of viral sequences of NB.1.8.1 overall, and the rapid rise of XFG, it would seem reasonable to expect XFG to become dominant very soon.
According to Australian data expert Mike Honey, the countries showing the highest rates of detection of XFG as of mid-June include India at more than 50%, followed by Spain at 42%, and the United Kingdom and United States, where the subvariant makes up more than 30% of cases.
In Australia as of June 29, NB.1.8.1 was the dominant subvariant, accounting for 48.6% of sequences. In the most recent report from Australia's national genomic surveillance platform, there were 24 XFG sequences with 12 collected in the last 28 days meaning it currently comprises approximately 5% of sequences.
When we talk about a new subvariant, people often ask questions including if it's more severe or causes new or different symptoms compared to previous variants. But we're still learning about XFG and we can't answer these questions with certainty yet.
Some sources have reported XFG may be more likely to course "hoarseness" or a scratchy or raspy voice. But we need more information to know if this association is truly significant.
Notably, there's no evidence to suggest XFG causes more severe illness compared to other variants in circulation or that it is necessarily any more transmissible.
Relatively frequent changes to the virus means we have continued to update the COVID vaccines. The most recent update, which targets the JN.1 subvariant, became available in Australia from late 2024. XFG is a descendant of the JN.1 subvariant.
Fortunately, based on the evidence available so far, currently approved COVID vaccines are expected to remain effective against XFG, particularly against symptomatic and severe disease.
Because of SARS-CoV-2's continued evolution, the effect of this on our immune response, as well as the fact protection from COVID vaccines declines over time, COVID vaccines are offered regularly, and recommended for those at the highest risk.
One of the major challenges we face at present in Australia is low COVID vaccine uptake. While rates have increased somewhat recently, they remain relatively low, with only 32.3% of people aged 75 years and over having received a vaccine in the past six months. Vaccination rates in younger age groups are significantly lower.
Although the situation with XFG must continue to be monitored, at present the WHO has assessed the global risk posed by this subvariant as low. The advice for combating COVID remains unchanged, including vaccination as recommended and the early administration of antivirals for those who are eligible.
Measures to reduce the risk of transmission, particularly wearing masks in crowded indoor settings and focusing on air quality and ventilation, are worth remembering to protect against COVID and other viral infections.
Given the number of times this has happened already, it should come as little surprise that we're now faced with yet another new subvariant of SARS-CoV-2, the virus responsible for COVID.
This new subvariant is known as XFG (nicknamed "Stratus") and the World Health Organization (WHO) designated it a "variant under monitoring" in late June. XFG is a subvariant of Omicron, of which there are now more than 1,000.
A "variant under monitoring" signifies a variant or subvariant which needs prioritised attention and monitoring due to characteristics that may pose an additional threat compared to other circulating variants.
XFG was one of seven variants under monitoring as of June 25. The most recent addition before XFG was NB.1.8.1 (nicknamed "Nimbus"), which the WHO declared a variant under monitoring on May 23.
Both nimbus and stratus are types of clouds.
Nimbus is currently the dominant subvariant worldwide - but Stratus is edging closer. So what do you need to know about Stratus, or XFG?
XFG is a recombinant of LF.7 and LP.8.1.2 which means these two subvariants have shared genetic material to come up with the new subvariant. Recombinants are designated with an X at the start of their name.
While recombination and other spontaneous changes happen often with SARS-CoV-2, it becomes a problem when it creates a subvariant that is changed in such a way that its properties cause more problems for us.
Most commonly this means the virus looks different enough that protection from past infection (and vaccination) doesn't work so well, called immune evasion. This basically means the population becomes more susceptible and can lead to an increase in cases, and even a whole new wave of COVID infections across the world.
XFG has four key mutations in the spike protein, a protein on the surface of SARS-CoV-2 which allows it to attach to our cells. Some are believed to enhance evasion by certain antibodies.
Early laboratory studies have suggested a nearly two-fold reduction in how well antibodies block the virus compared to LP.8.1.1.
The earliest XFG sample was collected on January 27.
As of June 22, there were 1,648 XFG sequences submitted to GISAID from 38 countries (GISAID is the global database used to track the prevalence of different variants around the world). This represents 22.7% of the globally available sequences at the time.
This was a significant rise from 7.4% four weeks prior and only just below the proportion of NB.1.8.1 at 24.9%. Given the now declining proportion of viral sequences of NB.1.8.1 overall, and the rapid rise of XFG, it would seem reasonable to expect XFG to become dominant very soon.
According to Australian data expert Mike Honey, the countries showing the highest rates of detection of XFG as of mid-June include India at more than 50%, followed by Spain at 42%, and the United Kingdom and United States, where the subvariant makes up more than 30% of cases.
In Australia as of June 29, NB.1.8.1 was the dominant subvariant, accounting for 48.6% of sequences. In the most recent report from Australia's national genomic surveillance platform, there were 24 XFG sequences with 12 collected in the last 28 days meaning it currently comprises approximately 5% of sequences.
When we talk about a new subvariant, people often ask questions including if it's more severe or causes new or different symptoms compared to previous variants. But we're still learning about XFG and we can't answer these questions with certainty yet.
Some sources have reported XFG may be more likely to course "hoarseness" or a scratchy or raspy voice. But we need more information to know if this association is truly significant.
Notably, there's no evidence to suggest XFG causes more severe illness compared to other variants in circulation or that it is necessarily any more transmissible.
Relatively frequent changes to the virus means we have continued to update the COVID vaccines. The most recent update, which targets the JN.1 subvariant, became available in Australia from late 2024. XFG is a descendant of the JN.1 subvariant.
Fortunately, based on the evidence available so far, currently approved COVID vaccines are expected to remain effective against XFG, particularly against symptomatic and severe disease.
Because of SARS-CoV-2's continued evolution, the effect of this on our immune response, as well as the fact protection from COVID vaccines declines over time, COVID vaccines are offered regularly, and recommended for those at the highest risk.
One of the major challenges we face at present in Australia is low COVID vaccine uptake. While rates have increased somewhat recently, they remain relatively low, with only 32.3% of people aged 75 years and over having received a vaccine in the past six months. Vaccination rates in younger age groups are significantly lower.
Although the situation with XFG must continue to be monitored, at present the WHO has assessed the global risk posed by this subvariant as low. The advice for combating COVID remains unchanged, including vaccination as recommended and the early administration of antivirals for those who are eligible.
Measures to reduce the risk of transmission, particularly wearing masks in crowded indoor settings and focusing on air quality and ventilation, are worth remembering to protect against COVID and other viral infections.
Given the number of times this has happened already, it should come as little surprise that we're now faced with yet another new subvariant of SARS-CoV-2, the virus responsible for COVID.
This new subvariant is known as XFG (nicknamed "Stratus") and the World Health Organization (WHO) designated it a "variant under monitoring" in late June. XFG is a subvariant of Omicron, of which there are now more than 1,000.
A "variant under monitoring" signifies a variant or subvariant which needs prioritised attention and monitoring due to characteristics that may pose an additional threat compared to other circulating variants.
XFG was one of seven variants under monitoring as of June 25. The most recent addition before XFG was NB.1.8.1 (nicknamed "Nimbus"), which the WHO declared a variant under monitoring on May 23.
Both nimbus and stratus are types of clouds.
Nimbus is currently the dominant subvariant worldwide - but Stratus is edging closer. So what do you need to know about Stratus, or XFG?
XFG is a recombinant of LF.7 and LP.8.1.2 which means these two subvariants have shared genetic material to come up with the new subvariant. Recombinants are designated with an X at the start of their name.
While recombination and other spontaneous changes happen often with SARS-CoV-2, it becomes a problem when it creates a subvariant that is changed in such a way that its properties cause more problems for us.
Most commonly this means the virus looks different enough that protection from past infection (and vaccination) doesn't work so well, called immune evasion. This basically means the population becomes more susceptible and can lead to an increase in cases, and even a whole new wave of COVID infections across the world.
XFG has four key mutations in the spike protein, a protein on the surface of SARS-CoV-2 which allows it to attach to our cells. Some are believed to enhance evasion by certain antibodies.
Early laboratory studies have suggested a nearly two-fold reduction in how well antibodies block the virus compared to LP.8.1.1.
The earliest XFG sample was collected on January 27.
As of June 22, there were 1,648 XFG sequences submitted to GISAID from 38 countries (GISAID is the global database used to track the prevalence of different variants around the world). This represents 22.7% of the globally available sequences at the time.
This was a significant rise from 7.4% four weeks prior and only just below the proportion of NB.1.8.1 at 24.9%. Given the now declining proportion of viral sequences of NB.1.8.1 overall, and the rapid rise of XFG, it would seem reasonable to expect XFG to become dominant very soon.
According to Australian data expert Mike Honey, the countries showing the highest rates of detection of XFG as of mid-June include India at more than 50%, followed by Spain at 42%, and the United Kingdom and United States, where the subvariant makes up more than 30% of cases.
In Australia as of June 29, NB.1.8.1 was the dominant subvariant, accounting for 48.6% of sequences. In the most recent report from Australia's national genomic surveillance platform, there were 24 XFG sequences with 12 collected in the last 28 days meaning it currently comprises approximately 5% of sequences.
When we talk about a new subvariant, people often ask questions including if it's more severe or causes new or different symptoms compared to previous variants. But we're still learning about XFG and we can't answer these questions with certainty yet.
Some sources have reported XFG may be more likely to course "hoarseness" or a scratchy or raspy voice. But we need more information to know if this association is truly significant.
Notably, there's no evidence to suggest XFG causes more severe illness compared to other variants in circulation or that it is necessarily any more transmissible.
Relatively frequent changes to the virus means we have continued to update the COVID vaccines. The most recent update, which targets the JN.1 subvariant, became available in Australia from late 2024. XFG is a descendant of the JN.1 subvariant.
Fortunately, based on the evidence available so far, currently approved COVID vaccines are expected to remain effective against XFG, particularly against symptomatic and severe disease.
Because of SARS-CoV-2's continued evolution, the effect of this on our immune response, as well as the fact protection from COVID vaccines declines over time, COVID vaccines are offered regularly, and recommended for those at the highest risk.
One of the major challenges we face at present in Australia is low COVID vaccine uptake. While rates have increased somewhat recently, they remain relatively low, with only 32.3% of people aged 75 years and over having received a vaccine in the past six months. Vaccination rates in younger age groups are significantly lower.
Although the situation with XFG must continue to be monitored, at present the WHO has assessed the global risk posed by this subvariant as low. The advice for combating COVID remains unchanged, including vaccination as recommended and the early administration of antivirals for those who are eligible.
Measures to reduce the risk of transmission, particularly wearing masks in crowded indoor settings and focusing on air quality and ventilation, are worth remembering to protect against COVID and other viral infections.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
ABC News
3 minutes ago
- ABC News
Pacific Islands race to contain 'largest dengue fever outbreak in a decade', as disease kills 18 people
When all four of Taloa Lam Shong's children were struck down with dengue fever in Samoa, she was on high alert. "I was scared and worried, knowing dengue fever had claimed children's lives," she said. Nearly 8,000 people have been diagnosed with the disease in Samoa this year, with children accounting for more than 70 per cent of cases, and six deaths reported. Cases are escalating fast in Samoa, which recorded more than 1,900 clinically diagnosed dengue cases last week. The Pacific's health authorities are scrambling to contain its spread across the region. It has killed 18 people, and the World Health Organization (WHO) says it is the largest outbreak in at least a decade. "This year has been another big peak of dengue, but the peak has been much bigger than any of the other peaks we've seen before," said Mark Jacobs, director of Pacific technical support at the WHO. Dengue fever is a viral infection transmitted between mosquitoes and humans, and outbreaks are often triggered by an infected person entering a country. When local mosquitoes bite them, they later transmit the disease by biting other people. Symptoms of dengue fever include high temperature, muscle aches, joint pain, nausea and vomiting. While most people recover within a week, in some cases worse symptoms arise after seven days — a sign that severe dengue fever is developing. "Really bad stomach pain, lots of vomiting, really rapid breathing, you can get bleeding from your gums, nose, or in your bowel movements, or in vomit," Dr Jacobs said. Samoan authorities are trying to contain the disease, fumigating schools and other facilities, and warning the public to take precautions. "It is important to heed the advice from the Ministry of Health," Samoa's prime minister, Fiame Naomi Mata'afa, said in a video broadcast online last week. "Please seek immediate medical assistance if your child develops dengue fever symptoms, do not wait until it is too late. "Early treatment can save lives." Experts say dengue fever has spread across the Pacific as people carrying the infection have travelled across the region. American Samoa, Tonga, French Polynesia, Kiribati and Tuvalu are grappling with cases. And in Samoa, Cook Islands and Nauru, the outbreak is still growing. In Nauru, the government said a 15-year-old boy and seven-year-old girl died on July 31 from dengue fever. Dr Jacobs said there had been 23,500 suspected cases of dengue fever, and more than 16,000 laboratory confirmed cases, across the Pacific this year. He said the region's climate made it vulnerable to outbreaks. Fiji has been the worst-hit among Pacific countries this year, reporting more than 14,000 suspected cases and 11,000 lab confirmed cases. But the outbreak in Fiji has peaked already and case numbers are decreasing. Its tourism authority has warned visitors to take precautions, and says Fiji's popular tourist areas and resorts are treated for mosquitoes. "If they're coming across to Fiji and they're staying in a modern resort or island resort or similar to that, the owners, general managers and staff of those locations are taking all the precautions they possibly can and putting a lot of things in place," Tourism Fiji chief executive Brent Hill said. "We haven't had too many reports [of infection] coming back from tourists. "We take it seriously and we try and do everything we can to minimise the risk. "Sadly, the prevalence of dengue fever in places like Fiji is often in our villages and often in parts of Fiji where tourists don't go." Dr Jacobs said it was estimated about half the world's population lived in areas at risk of dengue fever, and that 100 to 400 million cases were recorded each year. While there are no medications for it, experts say there are simple ways to avoid infection, including: "If you don't get bitten by mosquitoes, you don't get dengue," Dr Jacobs said. But he said people were not protected from severe cases if they had previously had dengue fever. "If you're getting dengue for the second time, you're much more likely to get severe dengue," he said. Dr Jacobs said anyone experiencing symptoms of severe dengue fever needed to act quickly. "If you go off and you get good quality care, then you're much less likely to die as a result of that." As the world awaits vaccines and medications for dengue fever, scientists looking to eliminate the disease are putting their hopes in bacteria called Wolbachia that live inside insects. University of Melbourne research fellow Perran Ross said they could block the transmission of viruses spread by mosquitoes. "It actually alters the reproduction, so that when the male mosquitoes have Wolbachia and the female mosquitoes don't, they don't produce any viable offspring," he said. "If you get enough mosquitoes in the wild that carry the Wolbachia, that can actually reduce their ability to spread viruses." Dr Ross said it had been used in places like Queensland, and was the reason the state no longer had local dengue transmission. "The bacteria that are being released around the world, it's reducing dengue by more than 50 per cent in some locations," he said. But Dr Ross said climate change was complicating efforts to control dengue fever, by increasing the number of habitats where disease-carrying mosquitoes could live and breed. In Samoa, families are monitoring for symptoms of dengue fever. "Many children in our family were infected with dengue fever, including all five of my sister's children and my 15-year-old daughter," Faalaniga Repoamo, a mother of six, said. "When our daughter was sick, we didn't leave it until it was too late, we saw the symptoms and rushed her to seek help. "Parents should stay alert and identify the symptoms early and take them to the hospital before their condition worsens."
Sydney Morning Herald
14 hours ago
- Sydney Morning Herald
Victoria spent over $1b on a surgery catch-up plan. The financial watchdog can't say if rapid clinics worked
Victoria's billion-dollar COVID catch-up plan for elective surgery fell short of its targets, and the effect of rapid surgical hubs on the health system remains unclear. The government program delivered 30,000 fewer catch-up operations than originally hoped, and this shortfall was driven by issues between the Health Department and the private hospitals tasked with carrying out extra public procedures, the Victorian Auditor-General's Office has found. In a report on its investigation, tabled in state parliament on Wednesday, the Auditor-General's Office determined that 209,925 elective procedures had been conducted in the 12 months to July last year – below the catch-up program's target of 240,000 procedures. The watchdog also heard that, as of May this year, there were 583 long-wait patients on the surgery waiting list. This group was already on the waiting list and overdue for surgery as of March 2022. The Auditor-General's Office heard from the department that the surgery shortfall was because private hospitals were either grappling with their own backlogs and infrastructure issues or asking for too much money as part of public-private surgery partnerships. It also heard from one health service that the modelling that helped shape the department's targets was flawed. The Andrews government allocated $1.5 billion to a surgery catch-up plan in April 2022, given the pandemic had triggered a backlog in elective procedures. What the Auditor-General's Office found 1. The department increased the number of planned surgeries and reduced the waiting list, but did not fully meet the plan's targets. 2. The shortfall against the overarching target was mainly from the public-in-private initiative. 3. The plan delivered additional facilities for planned surgeries, but their current and future effect on the health system's performance is unclear. As part of this program, which ran from April 2022 until June 30 last year, public health services were tasked with increasing their partnerships with private hospitals to deliver extra operations. These kinds of operations are called public-in-private surgeries. In the case of Frankston Private Hospital, one of the institutions to add a public surgical centre under the catch-up program, just over 6000 planned procedures were delivered in the 2023-24 financial year. The department's target was 9000 procedures.
The Age
14 hours ago
- The Age
Victoria spent over $1b on a surgery catch-up plan. The financial watchdog can't say if rapid clinics worked
Victoria's billion-dollar COVID catch-up plan for elective surgery fell short of its targets, and the effect of rapid surgical hubs on the health system remains unclear. The government program delivered 30,000 fewer catch-up operations than originally hoped, and this shortfall was driven by issues between the Health Department and the private hospitals tasked with carrying out extra public procedures, the Victorian Auditor-General's Office has found. In a report on its investigation, tabled in state parliament on Wednesday, the Auditor-General's Office determined that 209,925 elective procedures had been conducted in the 12 months to July last year – below the catch-up program's target of 240,000 procedures. The watchdog also heard that, as of May this year, there were 583 long-wait patients on the surgery waiting list. This group was already on the waiting list and overdue for surgery as of March 2022. The Auditor-General's Office heard from the department that the surgery shortfall was because private hospitals were either grappling with their own backlogs and infrastructure issues or asking for too much money as part of public-private surgery partnerships. It also heard from one health service that the modelling that helped shape the department's targets was flawed. The Andrews government allocated $1.5 billion to a surgery catch-up plan in April 2022, given the pandemic had triggered a backlog in elective procedures. What the Auditor-General's Office found 1. The department increased the number of planned surgeries and reduced the waiting list, but did not fully meet the plan's targets. 2. The shortfall against the overarching target was mainly from the public-in-private initiative. 3. The plan delivered additional facilities for planned surgeries, but their current and future effect on the health system's performance is unclear. As part of this program, which ran from April 2022 until June 30 last year, public health services were tasked with increasing their partnerships with private hospitals to deliver extra operations. These kinds of operations are called public-in-private surgeries. In the case of Frankston Private Hospital, one of the institutions to add a public surgical centre under the catch-up program, just over 6000 planned procedures were delivered in the 2023-24 financial year. The department's target was 9000 procedures.
